ArticlePloS one2026
The role of exosomal miRNA-125b derived from colon cancer-associated fibroblasts in skeletal muscle cachexia.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Extracellular vesicles in cancer-associated cachexia: molecular mechanisms and therapeutic perspectives.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer-associated cachexia is a multifactorial syndrome characterized by significant weight loss, primarily due to skeletal muscle atrophy. This condition impairs the quality of life and survival of patients with cancer. Although the mechanisms underlying cancer-associated cachexia, including exosomes and microRNAs (miRNAs), have been extensively explored, research specifically focusing on cancer-associated fibroblast (CAF)-derived exosomes is lacking. Therefore, in this study, we evaluated the effects of CAF-derived exosomal miRNAs from colon cancer on skeletal muscles using the Human Skeletal Muscle (HSkM) cell line. CAF-derived exosomes were isolated from colon cancer samples, and their effects on cell morphology were analyzed using confocal microscopy. The results indicate that treatment with CAF-derived exosomes significantly reduced myosin diameter. Moreover, miRNA sequencing revealed that miR-125b was enriched in CAF-derived exosomes. HSkM cells were subsequently transfected with a miR-125b mimic, which significantly reduced myosin diameter. Notably, co-treatment with CAF-derived exosomes and an miR-125b inhibitor reversed this effect. In conclusion, this study demonstrates the potential role of CAF-derived exosomes and miR-125b in cancer-associated cachexia, offering insights into the contribution of the tumor microenvironment and suggesting possible therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.